[Skip to Navigation]
Sign In
Views 274
Citations 0
Comment & Response
September 9, 2021

What Is the Optimal Treatment for Vulnerable Older Women With Ovarian Cancer?—Reply

Author Affiliations
  • 1GINECO, Laboratoire CarMEN de l’Université de Lyon, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre-Bénite, France, Lyon-Sud University Hospital, Lyon, France
  • 2GINECO, Hospices Civils de Lyon, Lyon, France
  • 3ARCAGY-GINECO, Université Paris Descartes, AP-HP, Paris, France
JAMA Oncol. 2021;7(11):1727. doi:10.1001/jamaoncol.2021.4131

In Reply We appreciate the opportunity to reply to comments regarding the perhaps counterintuitive and unexpected results from our randomized clinical trial on first-line chemotherapy in vulnerable older adult patients with cancer.1

Ito and Shimomura questioned the apparently lower feasibility of carboplatin monotherapy vs carboplatin–paclitaxel combinations. Importantly, despite a less favorable hematologic profile as previously reported,2 the decreased feasibility of carboplatin monotherapy in our study1 was more linked to an excess of early tumor progression rather than excess toxicity. Tumor progression was also more frequent with carboplatin monotherapy than a carboplatin–paclitaxel doublet in the NRG Oncology/Gynecologic Oncology Group GOG273 trial.3 Although the pejorative influence on overall survival of carboplatin monotherapy vs carboplatin–paclitaxel doublets has not always been confirmed, differing outcomes between regimens may be more obvious in our trial’s older population.1 Historical studies have highlighted the overly aggressive nature of ovarian cancer in older vs younger patients4 and a trend toward more extensive tumors,5 which may need more aggressive (doublet) chemotherapy.

Add or change institution
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×